As part of an investigation into the recent epidemic of deaths from asthma in New Zealand, trends in the sales of drugs for asthma in New Zealand, Australia, and the United Kingdom during 1975-81 were examined. Data on sales of drugs were obtained from an international pharmaceutical market research organisation. A striking increase in sales of sympathomimetic aerosols, steroid aerosols, and theophylline per caput occurred in all three countries, with the greatest increase occurring in New Zealand. Sales of sodium cromoglycate also increased in
Discussion
We believe that this is the first report of an interaction between salicylates and carbonic anhydrase inhibitors causing serious metabolic acidosis in patients with normal renal function. Previous reports of carbonic anhydrase inhibitors causing severe acidosis have been of patients in whom other predisposing factors have been present. '-5 In fact, acetazolamide has been used to treat salicylate poisoning. 6 The mechanism of this interaction, though not clear, may be related to hypocapnia induced by salicylate leading to a reduction in the carbon dioxide available for production of bicarbonate. Carbonic anhydrase inhibitors produce metabolic acidosis by their action on carbonic anhydrase in the proximal and distal renal tubules. This blocks excretion of hydrogen ions, producing an alkali urine. As acidosis develops, however, an increase occurs in the resorption of bicarbonate, which is independent of the activity of carbonic anhydrase; this limits the degree of acidosis that can be attributed to inhibition of carbonic anhydrase alone.7 In cases of renal failure the blocking of carbonic anhydrase activity leads to increasing acidosis because the capacity of the tubules to resorb bicarbonate is inadequate. Toxic doses of salicylates that result in metabolic acidosis are likely to have a detrimental effect in combination with carbonic anhydrase inhibitors. Serum salicylate concentrations of over 300 mg/l are required to produce a metabolic acidosis, 8 and in our two patients salicylate concentrations were below this at the time of presentation. Therapeutic doses of salicylates cause limited respiratory alkMlosis, but this fall in carbon dioxide tension has little effect on the production of bicarbonate unless the action of carbonic anhydrase is blocked, when the production of bicarbonate is much lower than if either mechanism were operating in isolation. The lack of bicarbonate ions would prevent excretion of hydrogen ions, thus causing increasingly severe acidosis.
Therapeutic doses of salicylates and carbonic anhydrase inhibitors given together seem to be capable of inducing potentially fatal metabolic acidosis in patients with normal renal and hepatic function. In such patients the doses should be kept to the minimum or salicylates replaced by an unrelated antiinflammatory agent. Serum bicarbonate concentrations should be estimated regularly and especially after any increase in the dosage.
These cases have been reported to the Committee on Safety of Medicines.
We thank Dr B M Ansell for allowing us to report details of patients under her care.
Introduction
New Zealand is experiencing a new epidemic of fatal asthma that is not occurring in other developed countries. ' and 69"o in Australia and the UK respectively ( fig 2) . Again, total sales in New Zealand in 1981 were more than twice those in the UK (2 6 times) and 1 9 times those in Australia.
Oral theophylline- Figure 3 shows the trends in sales of oral theophylline, which also increased in all three countries. Data were obtained for four categories of drugs that are used primarily in the treatment of asthma: inhaled steroids, sodium cromoglycate, sympathomimetic aerosols, and oral theophylline. Only adult doses and presentations were considered: syrups and tablets in paediatric doses were excluded from the analysis, as were all sympatho- 1981 sales more than trebled in New Zealand while in Australia and the UK they increased by 38°o and 30% respectively. In 1981 sales of theophylline in New Zealand were 1 6 times those in the UK and 1 3 times those in Australia. In all three countries in the period under consideration sales of the older forms of theophylline declined with a more than compensatory increase in sales of anhydrous and slow release forms.
Sodium cromoglycate-Sales of sodium cromoglycate during 1977-81 increased in New Zealand and the UK by 60°' and 200' respectively but declined by 1000 in Australia (fig 4) . Although between 1977 and BRITISH MEDICAL JOURNAL VOLUME 289
Discussion
Stimulated by the recent increase in mortality due to asthma in New Zealand,' we carried out this study to compare recent trends in the sales of drugs used in the treatment of asthma in New Zealand, the UK, and Australia, using data collected by Intercontinental Medical Statistics. A striking increase occurred in the sales of these drugs in each of the countries examined, particularly in New Zealand. The size of the increase in such a short time suggests that important changes have occurred in the pattern of the use of drugs for asthma.
An important consideration in a comparison of this type of information is the quality and uniformity of collection of data in each country. The annual sales data produced by Intercontinental Medical Statistics represent projections made from an analysis of a representative sample of retail pharmacies and are used as market research information by pharmaceutical firms. Collection of data is similar in each of the countries in which the company operates, and there were no major changes in the methods used during the time studied.
The data described here relate only to drugs prescribed through retail pharmacies, and it is possible that hospital prescribing may differ between countries. Intercontinental Medical Statistics now collects information on sales of drugs from hospitals as well as retail pharmacies in New Zealand and the UK (but not in Australia), and examination of these data does indicate differences in levels of hospital prescribing. In 1983 about 9% of all antiasthmatic preparations were dispensed through hospital pharmacies in the UK compared with 4% in New Zealand. Despite these differences, however, the proportion of antiasthmatic drugs prescribed through hospitals is small and would not account for the international differences in sales described here. Furthermore, with the increasing numbers of patients admitted to hospital with asthma in both countries over the past decade,' 6 it is likely that hospital prescribing for asthma has also increased. Overall sales would therefore probably show a greater increase than this report shows.
The increase in drug sales may represent an increase in the number of patients with asthma who are treated or an increase in the amount of treatment each patient receives, or both. Studies in New Zealand and the UK suggest that the prevalence of asthma has increased over the past 10-15 years.7 8 Moreover, it is possible that New Zealand has a greater prevalence of asthma than the two other countries examined, though this would explain only a small part of the increase in drug sales. Unfortunately, there appear to be no reported population based studies that have examined trends in the management of asthma with drugs.
A proportion of the increase may be attributable to changes in the prescribing of these drugs to treat other obstructive airways diseases. There are also some differences between the three countries in patterns of prescribing sympathomimetic tablets and syrups, which were not included in the analyses. These differences were examined, however, and were too small to account for the large increase seen in the sale of drugs. It Despite the recent introduction of new drugs and new formulations for the management of asthma and despite the major increase in sales of these drugs, mortality due to asthma has not declined. Indeed, New Zealand, which in this study had the largest sales of drugs to treat asthma per head of population and the greatest rate of increase in sales in recent years, had also had a recent increase in mortality due to asthma. ' As it appears unlikely that the increase in mortality due to asthma and sales of drugs to treat asthma in New Zealand can be explained solely by an increase in the prevalence or severity, or both, of asthma, alternative explanations need to be explored.
A previous epidemic of deaths due to asthma occurred in the mid-1960s in New Zealand, Australia, and England and Wales. ' Although an explanation for this epidemic has never been fully given, several workers have suggested that the introduction of pressurised aerosols containing sympathomimetics was a contributing factor.' It is therefore possible that the changing pattern of use of drugs to treat asthma in New Zealand could be one factor contributing to the recent increase in mortality due to asthma.
Direct drug toxicity, due to either individual drugs or combinations of drugs, has been implicated by some workers., 10 The temporal association between the recent increase in mortality due to asthma and in sales of drugs to treat asthma in New Zealand suggests, however, that this is unlikely. sented less than 1% of total sales of sympathomimetic aerosols.
Although this suggests that overuse of nebulisers is unlikely to be a major factor contributing to the current epidemic, the pattern of use may be more important than the total sales, but this cannot be examined in the present study.
One factor that may account in part for the difference in sales of drugs between the countries examined is the cost of prescriptions to the patient. In New Zealand the most frequently prescribed drugs used to treat asthma are free to the patient, whereas the charges for prescriptions in Australia and the UK may act as a financial disincentive. Furthermore, in New Zealand the cost of consultations with general practitioners may discourage patients from seeking the optimum supervision, whereas in the UK there is no financial barrier to consultations with general practitioners. The trends in sales of drugs to treat asthma shown here may reflect international differences in prescribing patterns for all drugs. Indeed, international comparisons of use of drugs per head of population have shown more than twofold differences between countries. '4 In the absence of comparable data on trends in prevalence and severity of asthma in the countries investigated, the interpretation of our data can only be speculative. Nevertheless, the results of this study show that a dramatic increase in per caput sales of drugs to treat asthma has not been associated with a reduction in mortality due to asthma. The dose of intravenous diazepam required for sedation was estimated in a series of 78 patients aged 17-85 years given the drug for dental and endoscopic procedures. Multiple regression analysis showed a significant correlation (r=071; p <0001) between dose and age, body weight, the taking of regular sedation, and the taking of more than 40 g alcohol daily, but there were no differences in the doses required between men and women, smokers and non-smokers, inpatients and outpatients, or dental and endoscopy patients. Patients aged 80 required an average dose of 10 mg and patients aged 20 an average dose of 30 mg, and the dose required was much higher in those receiving regular sedation or having a high alcohol intake.
Plasma total and free diazepam concentrations were measured in the second half of the series of patients Introduction The doses of diazepam needed to produce the same degree of sedation varies widely among patients. There is little information about the factors which alter diazepam tolerance and which might be used to predict the dose required. The neurological response to diazepam has been reported to increase with age,' 2 but those results may have been influenced by the selection and distribution of patients,' and the use of additional premedications.I There is also evidence that patients who take the drug regularly, cigarette smokers,3 and those who take large amounts of alcohol regularly,4 may be more tolerant of its effects.
Diazepam is highly bound to plasma proteins and only the unbound fraction is available for distribution in the tissues. Plasma binding decreases with age,5-and it has been suggested that the rise in free drug concentration will lead to an increase in the clinical response.7 We have studied the relation between the dose of diazepam required for sedation and the factors that have been reported to alter the clinical response. The degree total and free diazepam concentrations were also measured to assess the extent to which the clinical response is determined by pharmacokinetic factors.
